Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Teva plans to raise Mylan bid by as much as $2 billion: Bloomberg | Reuters
Teva makes $40B offer for Mylan
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
ADHD Drug Adderall Supply Delays Likely to Continue for 2-3 Months, Teva Says - Bloomberg
Teva's $4 Billion Medicine Faces Patent Judgment Day in U.S. - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - BNN Bloomberg
Teva CEO to Meet Netanyahu With Blunt Message on Need for Cuts - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
